InvisiMask

N/A

Report date: 2025/01/26 16:11:13

Base Information

Drug NameInvisiMask
Drug Alias NameSARS-CoV-2 spike glycoprotein modulator (Eureka Therapeutics)anti-SARS-CoV-2 human monoclonal antibody (Eureka Therapeutics)anti-SARS-CoV-2 spike human mAb (Eureka Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAngiotensin-converting enzyme 2 modulatorsCoronavirus spike glycoprotein modulators
TargetsAngiotensin-converting enzyme 2Coronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEureka Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEureka Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A